Stockreport

ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor

Oric Pharmaceuticals, Inc.  (ORIC) 
PDF SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on de [Read more]